Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Average Rating of “Buy” from Brokerages

Shares of Siemens Healthineers AG (OTCMKTS:SMMNY) have been assigned an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and three have given a strong buy recommendation to the company.

Several equities research analysts have commented on the company. Citigroup restated a “buy” rating on shares of Siemens Healthineers in a research note on Friday, January 23rd. Sanford C. Bernstein upgraded Siemens Healthineers to a “strong-buy” rating in a research note on Tuesday, January 13th. Finally, Zacks Research upgraded Siemens Healthineers from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th.

Siemens Healthineers Stock Performance

Shares of OTCMKTS:SMMNY opened at $22.84 on Monday. The business has a 50-day moving average of $22.70 and a two-hundred day moving average of $24.99. Siemens Healthineers has a 12 month low of $20.39 and a 12 month high of $28.92.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.